Plain-English translation of NCT05519111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing —a medication derived from cannabis—to see if it can help people with sickle cell disease manage pain and reduce inflammation in their bodies. About 60 adults with sickle cell disease will participate, with half receiving the medication and half receiving a placebo (a pill with no active ingredients). The study will last 8 weeks and measure how much the medication helps with pain, quality of life, and inflammation markers.
People with sickle cell disease often experience severe, ongoing pain and inflammation that can significantly affect their daily lives, and current pain management options don't work well for everyone. Researchers want to see if this medication could offer another treatment option to help manage these symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to either receive the medication or a placebo, taking pills twice a day for 8 weeks. During the first few days, your dose will be personalized—starting at 5 mg twice daily and adjusted between 2.5 mg and 10 mg twice daily based on what works best for you and how you feel. Throughout the study, researchers will monitor your pain levels, quality of life, inflammation markers through blood tests, and how well you tolerate the treatment compared to the placebo group.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Enrollment target
~60 participants
Started
April 2025
Primary completion
April 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Susanna Curtis, MD, PhD
MOUNT SINAI HOSPITAL
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.